G1 Therapeutics (GTHX) Set to Announce Earnings on Wednesday

G1 Therapeutics (NASDAQ:GTHX) is scheduled to release its earnings data before the market opens on Wednesday, May 1st. Analysts expect G1 Therapeutics to post earnings of ($0.19) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Wednesday, February 28th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.06. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The firm had revenue of $14.87 million during the quarter, compared to the consensus estimate of $12.83 million. During the same quarter in the previous year, the company posted ($0.73) earnings per share. On average, analysts expect G1 Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

G1 Therapeutics Trading Down 6.8 %

Shares of NASDAQ:GTHX opened at $3.72 on Tuesday. G1 Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.00. The company has a current ratio of 3.87, a quick ratio of 3.45 and a debt-to-equity ratio of 1.46. The company’s 50 day moving average is $3.78 and its 200 day moving average is $3.02.

Insider Activity

In related news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the sale, the insider now directly owns 169,938 shares of the company’s stock, valued at $785,113.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GTHX. Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of G1 Therapeutics in a report on Friday, April 12th. Wedbush reissued an “outperform” rating and issued a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.